Augurex

Augurex is a clinical diagnostics leader advancing biomarker-based tests for autoimmune diseases to improve patient outcomes.

[Augurex @Augurex]

Augurex has been named a finalist in the ADLM 2026 Disruptive Technology Award for SPINEstat® (Anti-14-3-3eta Multiplex), a first-in-class diagnostic for earlier identification of #axSpA. Presenting at #ADLM2026 on July 27 in Anaheim. #SPINEstat #ADLM2026 https://t.co/eU7LM0egTZ

[Augurex @Augurex]

May 20 is #AutoimmuneArthritisDay, where the focus is on conditions driven by immune-mediated inflammation that can lead to joint damage. Diagnosis is often delayed, and better insight into disease biology can help bring clarity earlier.

[Augurex @Augurex]

May is #ArthritisAwarenessMonth, where we recognize arthritis is more than joint pain. It can lead to progressive damage and loss of function if not identified early. Earlier insight matters, and Augurex’s diagnostic solutions help bring clarity to disease management.

[Augurex @Augurex]

May 2 is #WorldASDay. axSpA often begins with persistent back pain and stiffness, yet diagnosis can take 7 to 10 years. Symptoms are frequently attributed to non-inflammatory causes before the right diagnosis is made. Early detection improves long-term outcomes.

[Augurex @Augurex]

As part of #SpondyloarthritisAwarenessMonth, it is important to recognize that these diseases are often under-identified, leading to long and uncertain diagnostic journeys. Improving early identification can change outcomes and bring more clarity to patient care.

[Augurex @Augurex]

Augurex will attend SPARTAN 2026, May 14-16 in Toronto. We're proud to support the axSpA community with SPINEstat®, a first-in-class diagnostic enabling earlier axSpA identification & differentiation from mechanical back pain. Attending? Let's connect. https://t.co/Pyp2zohhHM

[Augurex @Augurex]

Augurex will be attending the Northwest Rheumatism Society Annual Meeting, April 30 – May 2, 2026 in Vancouver, Canada. If you're attending, we’d welcome the opportunity to connect. Reach out to coordinate a time during the meeting. Learn more: https://t.co/CWqkQwpoYE #NWRS

[Augurex @Augurex]

Augurex will be exhibiting at #CCREast, April 30 - May 3 in Destin, FL. Visit us at Booth 64 to learn how JOINTstat® (14-3-3eta) for RA and SPINEstat® (Anti-14-3-3eta Multiplex) for axSpA support earlier identification and more confident care decisions. https://t.co/pXhCqFC1lm

[Association for Diagnostics & Laboratory Medicine @myADLM]

We are thrilled to announce the semifinalists for the 2026 Disruptive Technology Award Competition! These gamechangers developed innovative and cutting-edge diagnostic solutions to improve patient care: https://t.co/Hb3bftWgz2

[Augurex @Augurex]

Augurex is proud to be named a semifinalist for the ADLM 2026 Disruptive Technology Award for SPINEstat® (Anti‑14‑3‑3eta Multiplex), a first‑in‑class diagnostic designed to support earlier identification of #axial #spondyloarthritis. #ADLM2026 #SPINEstat
https://t.co/eU7LM0egTZ

[Augurex @Augurex]

Neil Klompas, CEO of Augurex, will be in Toronto this April for the Mintz Life Sciences Matchmaking Day (Apr 20) and Bloom Burton Healthcare Investor Conference (Apr 21–22). Looking forward to connecting with investors and partners. https://t.co/tbUkmfw0tP https://t.co/4e8w5jn9fo

[Augurex @Augurex]

Augurex will be attending and presenting new data at #BSR2026, April 28–30 in Glasgow, showcasing JOINTstat® (14-3-3eta) for RA and SPINEstat® (Anti-14-3-3eta Multiplex) for axSpA, with poster presentations across both disease areas. Reach out to schedule a meeting.

[Augurex @Augurex]

March 18th is World Young Rheumatic Diseases Day. Too many young patients face delayed recognition of inflammatory arthritis and axSpA. Earlier answers can change outcomes. At Augurex, we’re committed to reducing diagnostic delay and supporting timely care. #WORDDay2026

[Augurex @Augurex]

March is Autoimmune Awareness Month. Autoimmune diseases are often invisible & misunderstood, leading to delayed diagnosis. We’re committed to reducing diagnostic delay & supporting earlier identification to improve patient outcomes. #AutoimmuneAwarenessMonth #InflammatoryDisease

[Augurex @Augurex]

Neil Klompas, CEO & President of Augurex, will be at the TD Cowen 2026 Healthcare Conference in Boston, March 2–4. Attending and interested in connecting to discuss our diagnostic portfolio and growth strategy? Reach out to coordinate a meeting. #TDCowen #Biotech #Augurex

[Augurex @Augurex]

Rheumatoid arthritis is more than joint pain. On RA Awareness Day, we recognize the daily impact of RA and are proud of Augurex’s commitment to advancing diagnostics that support better outcomes. You are not alone. @ArthritisSoc @ArthritisFdn

[Augurex @Augurex]

Honored to be featured by Moira Gunn of @NPR's #BioTechNation as one of the Top 5 JPM interviews. In this special edition, Augurex shares how we’re closing gaps in back pain and axSpA care, where patients often wait 7–10 years for answers. #JPM2026 https://t.co/AhA9KwOiWw

[Augurex @Augurex]

We’re excited to see the @spondylitis Association of America feature Augurex’s latest ACR 2025 data in a new article and eSUN newsletter. The coverage highlights how SPINEstat® (Anti-14-3-3eta Multiplex test) may help improve early axSpA diagnosis & care. https://t.co/0vKue6215g

[Augurex @Augurex]

Augurex CEO Neil Klompas joins the @ProgressPotent1 podcast for the episode “Ending Diagnostic Delays in Autoimmune Conditions” to discuss how SPINEstat® supports earlier, more accurate detection of #axSpA and helps address long diagnostic delays. 🎧 https://t.co/TUEUOh961v

[Augurex @Augurex]

Excited to see Dr. @nbiln featured on the @spondylitis Spondycast #Podcast discussing how biomarkers & tools like SPINEstat® can help reduce diagnostic delays in axSpA by improving early detection & referral accuracy. Listen here: https://t.co/JNQ30ZkazF